Table 1 Baseline characteristics of patients

Gender

Male

99 (83.2)

Female

20 (16.8)

Age (y)

(Median, range)

65(42–90)

< 65

69 (58)

≥ 65

50 (42)

Smoking history

No

69 (58)

Yes

50 (42)

KPS score

< 80

4 (3.4)

≥ 80

115 (96.6)

PTV-dose (Gy)

(Median, range)

60 (45–75)

< 50

6 (5.0)

50–60

103 (86.6)

> 60

10 (8.4)

Fractiondose (Gy)

(Median, range)

2 (1.5-8)

> 3

14 (11.8)

≤ 3

105 (88.2)

Number of cycles of bevacizumab before radiotherapy

≤ 4

26 (21.8)

> 4

93 (78.2)

PTV-volume (cm³)

(Median, range)

183.85(20.2-950.4)

≤ 183.85

74 (62.2)

> 183.85

45 (37.8)

V₂₀ total (%)

(Median, range)

13.2 (8.2–33.3)

≤ 25

108 (90.8)

> 25

11 (9.2)

V₅ total (%)

(Median, range)

29.4 (10.4–86.7)

≤ 60

114 (95.8)

> 60

5 (4.2)

Timing of radiotherapy addition

Consolidation

106 (89.1)

Salvage

13 (10.9)

Chemotherapy regimen

PP

111 (93.3)

TP

8 (6.7)